Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$2.05
+$0.04 · +1.99%
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Latest quote
$2.05
+$0.04 · +1.99%
After-hours
$2.05
$0.00 · 0.00%
Sep 10, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Day range
Current $2.05
52-week range
Current $2.05
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
57
Mixed
Risk
74
High Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Day range
Current $2.05
52-week range
Current $2.05
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 81K USD | 77K USD | 306K USD | 268K USD | 82K USD |
| Cost of goods sold | 164K USD | 82K USD | 210K USD | 193K USD | 37K USD |
| Gross profit | −83K USD | −5K USD | 96K USD | 75K USD | 45K USD |
| Research and development | 13.17M USD | 14.73M USD | 15.23M USD | 14.24M USD | 11.02M USD |
| Selling, general, and administrative | 23.25M USD | 21.9M USD | 24.69M USD | 31.48M USD | 24.42M USD |
| Operating expenses | 36.42M USD | 36.63M USD | 39.92M USD | 45.73M USD | 35.44M USD |
| Interest income | 4.59M USD | 2.75M USD | 1.64M USD | 456K USD | 145K USD |
| Interest expense | 9K USD | 28K USD | 55K USD | 61K USD | 746K USD |
| Depreciation and amortization | 940K USD | 833K USD | 900K USD | 756K USD | 659K USD |
| Operating income | −36.5M USD | −36.64M USD | −39.82M USD | −45.65M USD | −35.4M USD |
| Net income | −31.93M USD | −32.9M USD | −36.24M USD | −44.19M USD | −35.01M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.81M0.00%2.3T USD0.03%$373.24-0.62%
Vanguard Extended Market ETFVXF775.63K0.00%93.7B USD0.05%$236.16-1.05%
iShares Micro-Cap ETFIWC203.37K0.01%1.49B USD0.60%$190.1-1.22%
Avantis U.S. Small Cap Equity ETFAVSC10.86K—3.1B USD0.25%$71.10-0.71%
Dimensional - US Core Equity 1 ETFDCOR10.2K0.00%3.51B USD0.14%$83.29-0.48%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCDimensional - US Core Equity 1 ETFDCORAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
